[ad_1]
🔎 Novo Nordisk (NVO), (DK: NOVO.B): The drugmaker said a trial showed its blockbuster diabetes drug, Ozempic, could delay kidney disease’s progression. Novo stock rose over 3% in Danish trading. Stocks in dialysis-services providers DaVita (DVA) and Fresenius (XE:FRE), (FMS) tumbled in premarket trading following the news.
[ad_2]
Source link
